Menu
GOVPH
  • Home
  • HTA Governance
    • Universal Health Care Act
    • Administrative Order on HTA
    • Philippine HTA Process Guide
    • Philippine HTA Methods Guide
    • Philippine HTA Code of Conduct
    • HTA Philippines Social Values Guide
  • About Us
    • Mission/Vision
    • Health Technology Assessment Council (HTAC)
    • Health Technology Assessment Division (HTAD)
    • HTA Philippines Annual Report
      • 2021 HTA Annual Report
      • 2020 HTA Annual Report
      • 2019 HTA Annual Report
    • Road to HTA Institutionalization
    • External Partners
  • Assessments
  • Issuances
  • Evidence Briefs
  • FAQs
  • Get Involved with Us
    • Careers
    • Contact Us
    • Call for Nomination
    • Topic Nomination
  • AUXILIARY MENU
  • GOVPH
  • Home
  • HTA Governance
    • Universal Health Care Act
    • Administrative Order on HTA
    • Philippine HTA Process Guide
    • Philippine HTA Methods Guide
    • Philippine HTA Code of Conduct
    • HTA Philippines Social Values Guide
  • About Us
    • Mission/Vision
    • Health Technology Assessment Council (HTAC)
    • Health Technology Assessment Division (HTAD)
    • HTA Philippines Annual Report
      • 2021 HTA Annual Report
      • 2020 HTA Annual Report
      • 2019 HTA Annual Report
    • Road to HTA Institutionalization
    • External Partners
  • Assessments
  • Issuances
  • Evidence Briefs
  • FAQs
  • Get Involved with Us
    • Careers
    • Contact Us
    • Call for Nomination
    • Topic Nomination

COVID -19 Investigational Drugs

COVID – 19 Investigational drugs

HTAC interim recommendation on the use of casirivimab+imdevimab for the treatment of COVID-19

December 29, 2021

Remdesivir, Tocilizumab, Baricitinib, and Favipiravir

May 12, 2021

Dexamethasone

May 12, 2021

Favipiravir

July 30, 2020

Cycloferon

July 30, 2020